Abnormal expression of CD66a promotes proliferation and inhibits apoptosis of human leukemic B cells in vitro

Abstract

The aberrant expression of myeloid antigen CD66 on acute B-lymphoblastic leukemia (B-ALL) cells is a well-documented phenomenon. CD66a is a major subtype of the CD66 family which plays a dual role in different cancers, and the contradictory effect may depend on the isoform ratio of CD66a-4L to CD66a-4S. Although the abnormal expression of CD66a on leukemic B-cells has been reported widely, little is known about the biological function of this aberrant expression. In this study, we showed that inhibition of CD66a in human B-ALL cell lines reduced the cellular proliferative rate and increased the percentage of cellular apoptosis, and the ratio of CD66a-4L to CD66a-4S in leukemic B cells is much higher than that in granulocytes. In addition, alteration of the L:S ratio by silencing and overexpressing the L isoform in B-ALL cell lines confirmed that a high L:S ratio of CD66a in leukemic B cells promotes proliferation and inhibits FasL-induced apoptosis.

Keywords::

• CD66a
• acute leukemic B cells
• proliferation
• apoptosis

Acknowledgement

This work was supported by the Intramural Research Program of China Medical University.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.